Drug comparisons
Alogliptin vs Sotagliflozin
Alogliptin vs Sotagliflozin: DPP-4 vs dual SGLT inhibitors for type 2 diabetes. Compare glycemic control, heart failure risks, CV benefits, and safety.
No comparison dimensions are available for this page.
Clinical context
This comparison is triggered for type 2 diabetes patients with cardiovascular disease or heart failure when choosing between a DPP-4 inhibitor and a dual SGLT inhibitor.
Bottom line
Sotagliflozin often suits those with heart failure or CV risk better, while Alogliptin may suffice for straightforward glycemic control, but individual factors decide.
All medication comparisons